Organon & Co at JPMorgan Healthcare Conference Transcript

Jan 10, 2022 / 07:15PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat with the Organon management team today. From the company, we have Kevin Ali, the company's CFO (sic -- CEO); as well as Matt Walsh, the company's CFO. So Kevin and Matt, Happy New Year, and thanks for speaking with us today.

Kevin Ali - Organon & Co. - CEO & Director

A pleasure.

Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

Excellent. Well, this is your first presentation at the JPMorgan Healthcare Conference post the Merck spin. And would love to maybe kick off the conversation with just some opening remarks from both of you as you think about Organon's positioning, as we think about the -- kind of the spin out of Merck and heading into 2022. So with that, maybe turn it over to Kevin.

Kevin Ali - Organon & Co. - CEO & Director

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot